The rejection of Acomplia doesn’t make crusader Steven Nissen look good:
That means it’s at least the second time in under a year that Steven Nissen has been wrong about the promise of new drugs. Nissen, of course, is the well-known Cleveland Clinic cardiologist whose efforts were largely responsible for toppling Vioxx, and he just co-authored a NEJM study raising serious doubts about Avandia.
He was also optimistic about Pfizer-dud torcetrapib. (via WSJ Health Blog)
Related posts:
- Conflict of interest and Steven Nissen, the next potental head of the FDA
- RIP Torcetrapib
- Is the pressure getting to Steven Nissen?
- Did the Avandia scare harm patients, and is Steven Nissen to blame?
- Taking Steven Nissen to task
- Nissen pumps up Actos
- Nissen angling for the FDA?
KevinMD.com on Facebook
 
Follow on Twitter  
Subscribe








Comments on this entry are closed.